AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Translation initiation factor eIF-2B subunit gamma

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9NR50

UPID:

EI2BG_HUMAN

Alternative names:

eIF-2B GDP-GTP exchange factor subunit gamma

Alternative UPACC:

Q9NR50; B2RBH8; D3DPZ2; Q5QP89; Q5QP90; Q8NDB5; Q8WV57; Q9H850

Background:

Translation initiation factor eIF-2B subunit gamma, also known as eIF-2B GDP-GTP exchange factor subunit gamma, plays a crucial role in protein synthesis by catalyzing the exchange of eukaryotic initiation factor 2-bound GDP for GTP. This process is vital for the initiation phase of protein synthesis, making it a key player in cellular function and health.

Therapeutic significance:

Leukoencephalopathy with vanishing white matter 3, a progressive brain disease, is linked to mutations affecting this protein. Understanding the role of Translation initiation factor eIF-2B subunit gamma could open doors to potential therapeutic strategies for this debilitating condition, highlighting its importance in medical research.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.